Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Rocket Pharmaceuticals, Inc. - Common Stock (NQ:RCKT)

3.675 -0.035 (-0.94%)
Streaming Delayed Price Updated: 10:39 AM EDT, Sep 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Rocket Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
News headline image
These 3 Clinical-Stage Biotech Stocks Can Offer Exponential Gains ↗
These biotech stocks, lacking in profitability but seeding huge potential, should be on your watchlist. 
Via Talk Markets
News headline image
Rocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Analyst Ratings for Rocket Pharmaceuticals ↗
 
Via Benzinga
News headline image
RCKT Stock Earnings: Rocket Pharmaceuticals Beats EPS for Q1 2024 ↗
RCKT stock results show that Rocket Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI™ (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
7 Speculative Stocks to Double Your Money THIS Year ↗
Although terribly risky, these stocks to double your money could be enticing if you have some pocket change lying around. 
Via InvestorPlace
News headline image
Rocket Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Rocket Pharmaceuticals Appoints R. Keith Woods to Board of Directors
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Merit Medical Systems And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
U.S. stock futures traded lower this morning, with the Dow Jones futures falling more than 40 points on Monday. 
Via Benzinga
Topics Stocks
News headline image
Rocket Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Progress
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Rocket Pharmaceuticals Stock Sees Improved Price Strength ↗
On Thursday, Rocket Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 68 to 78 
Via Investor's Business Daily
News headline image
Rocket Pharmaceuticals Stock Sees RS Rating Pops Higher ↗
A Relative Strength Rating upgrade for Rocket Pharmaceuticals shows improving technical performance. Will it continue? 
Via Investor's Business Daily
News headline image
Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral and AAV Gene Therapies at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023 ↗
 
Via Benzinga
News headline image
Rocket Pharmaceuticals Announces FDA Acceptance of Biologics License Application with Priority Review for RP-L201 (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Rocket Pharmaceuticals to Participate in the Chardan 7th Annual Genetic Medicines Conference
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Better Gene Editing Stock: Intellia Therapeutics vs. Rocket Pharmaceuticals ↗
Rocket could launch its medicines sooner, but Intellia is aiming for larger markets. 
Via The Motley Fool
News headline image
Rocket Pharmaceuticals Stock Is Blasting Off, but Here's Why You Should Tread Carefully ↗
Its near-term risks are subtle but bigger than their flying stock price might indicate. 
Via The Motley Fool
News headline image
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet ↗
Investors are on the hunt for undervalued, under followed and emerging stocks. Retail traders have countless methods at their disposal to uncover new information. For some, this may be overwhelming. 
Via Benzinga
News headline image
Dow Turns Lower; KULR Technology Group Shares Plummet ↗
U.S. stocks traded mixed toward the end of trading, with the Dow Jones falling 100 points on Wednesday. The Dow traded down 0.29% to 34,545.66 while the NASDAQ rose 0.22% to 13,803.43. The S&P 500,... 
Via Benzinga
Topics Stocks
News headline image
Why Is Rocket Pharmaceuticals (RCKT) Stock Up 35% Today? ↗
With Rocket Pharmaceuticals reaching a Phase II agreement with the FDA, RCKT stock soared, though some concerns linger. 
Via InvestorPlace
News headline image
Why Eiger BioPharmaceuticals Shares Are Trading Lower By 52%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Avalo Therapeutics, Inc. (NASDAQ: AVTX) shares surged 68% to $0.2075. Avalo Therapeutics, on Sept 12, got notice from the Nasdaq as of Sept 11 the company’s securities had closing bid price of... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Dow Gains 50 Points; US Crude Oil Inventories Rise ↗
U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 50 points on Wednesday. The Dow traded up 0.16% to 34,701.06 while the NASDAQ rose 0.44% to 13,834.85. The S&P 500,... 
Via Benzinga
Topics Stocks
News headline image
Why Shares of Rocket Pharmaceuticals Are Taking Off on Wednesday ↗
The late-stage pharmaceutical company said it had reached an agreement with the Food and Drug Administration regarding a phase 2 trial for a Danon disease therapy. 
Via The Motley Fool
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.